Neoadjuvant FOLFOXIRI Chemotherapy Alone for Locally Advanced Rectal Cancer
Status:
Completed
Trial end date:
2017-08-15
Target enrollment:
Participant gender:
Summary
The standard treatment for stage 2/3 rectal cancer is neoadjuvant 5-Fu based chemoradiation.
However, preoperative radiation cause kinds of adverse events, some were irreversible. And
the survival benefit was not obvious. Whether chemotherapy alone is effective enough in
treating rectal cancer is not yet known. Here, the investigators chose all the three active
cytotoxic agents (5-FU, Oxaliplatin, Irinotecan) as the neoadjuvant treatment regimen
(FOLFOXIRI). The purpose of the study is to evaluate the efficacy of FOLFOXIRI as neoadjuvant
regimen in treating patients with locally advanced rectal cancer.